Technology area: Biotechnology & Pharmaceuticals
35 pending office actions • 14 art units • 25 examiners • 2 of 35 (6%) have an AI response strategy ready • 26 patents granted in the last 365 days
INCYTE Corporation manages a robust portfolio with 36 pending office actions in the Biotechnology & Pharmaceuticals technology area. This high volume of activity is spread across 26 distinct examiners and 14 distinct art units. The breadth of the portfolio across 14 distinct art units indicates a diverse range of pharmaceutical and biological subject matter currently under review by the patent office.
CHAO, ALLEN is the busiest examiner for the company, currently overseeing 4 pending office actions. While CHAO, ALLEN has the highest individual count, the 26 distinct examiners involved show that the majority of the 36 pending actions are handled by different individuals. This distribution requires a broad prosecution strategy that accounts for the varied practices across many different art units and examiners.
Practitioners managing this portfolio must navigate a complex landscape of 14 distinct art units. The high volume of 36 pending actions suggests a continuous and active filing strategy within the biotechnology sector. Success across such a broad array of examiners and units depends on maintaining consistent arguments while addressing the specific technical nuances required by each of the 26 different officials involved in the review process.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 7 (20%) |
| §102 only | 1 (3%) |
| §112 only | 10 (29%) |
| Double-patenting only | 5 (14%) |
| Double-patenting + other | 4 (11%) |
| Multi-statute (no §101) | 7 (20%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHAO, ALLEN | 4 | 60.0% | +0.0% |
| AULAKH, CHARANJIT | 3 | 80.7% | -14.5% |
| RAHMANI, NILOOFAR | 2 | 77.6% | -2.9% |
| REDWOOD, CHRISTOPHER EVAN | 2 | 0.0% | +0.0% |
| SHIAO, REI TSANG | 2 | 79.9% | -33.5% |
| GAO, ASHLEY HARTMAN | 2 | 56.5% | +38.0% |
| DAHLE, CHUN WU | 2 | 50.2% | +51.1% |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18960485 | SALTS OF TAM INHIBITORS | WARD, PAUL V | — |
| 18939388 | DERIVATIVES OF AN FGFR INHIBITOR | AULAKH, CHARANJIT | — |
| 18678931 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | AULAKH, CHARANJIT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18232970 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | REDWOOD, CHRISTOPHER EVAN | 25d overdue |
| 18056907 | MULTISPECIFIC BINDING MOIETIES COMPRISING PD-1 AND TGF-BRII BINDING DOMAINS | CUNNINGCHEN, KATHLEEN MARY | 15d |
| 18980424 | BICYCLOOCTANE KRAS INHIBITORS | RAHMANI, NILOOFAR | — |
| 18871262 | BICYCLIC AMINE CDK12 INHIBITORS | AULAKH, CHARANJIT | — |
| 18941025 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | REDWOOD, CHRISTOPHER EVAN | — |
| 18581959 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — |
| 18411350 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — |
| 18245019 | TOPICAL TREATMENT OF VITILIGO | SOROUSH, LAYLA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18625703 | NOVEL PD-1 BINDING DOMAINS | GAO, ASHLEY HARTMAN | 15d |
| 18973200 | RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS | WELLS, LAUREN QUINLAN | — |
| 18953578 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS | NESTOR, DONNA MICHELLE | — |
| 18625756 | NOVEL PD-1 BINDING DOMAINS | GAO, ASHLEY HARTMAN | — |
| 18581959 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — |
| 18411350 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | — |
| Art Unit | Apps |
|---|---|
| 1622 | 8 |
| 1621 | 5 |
| 1691 | 4 |
| 1629 | 3 |
| 1627 | 2 |
| 1625 | 2 |
| 1678 | 2 |
| 1641 | 2 |
| 1646 | 2 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18980424 | BICYCLOOCTANE KRAS INHIBITORS | RAHMANI, NILOOFAR | 1691 | §102§112 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18973200 | RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS | WELLS, LAUREN QUINLAN | 1622 | Other | Non-Final OA | — | AI Ready | Dec 09, 2024 |
| 18871262 | BICYCLIC AMINE CDK12 INHIBITORS | AULAKH, CHARANJIT | 1621 | §103§112 | Non-Final OA | — | Pending | Dec 03, 2024 |
| 18960485 | SALTS OF TAM INHIBITORS | WARD, PAUL V | 1622 | DP | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18953578 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS | NESTOR, DONNA MICHELLE | 1627 | DP | Non-Final OA | — | Pending | Nov 20, 2024 |
| 18941025 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | REDWOOD, CHRISTOPHER EVAN | 1629 | §103§112 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18939388 | DERIVATIVES OF AN FGFR INHIBITOR | AULAKH, CHARANJIT | 1621 | §112Other | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18827269 | Kinase Inhibitors | SHIAO, REI TSANG | 1691 | DP | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18824281 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | CHEN, PO-CHIH | 1621 | §103 | Non-Final OA | 295d overdue | Pending | Sep 04, 2024 |
| 18821138 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | SHIAO, REI TSANG | 1691 | §102§103DP | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18807221 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | RZECZYCKI, PHILLIP MATTHEW | 1625 | §112 | Non-Final OA | — | Pending | Aug 16, 2024 |
| 18777124 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | SHTERENGARTS, SAMANTHA L | 1623 | DP | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18736628 | BICYCLIC AMINES AS CDK2 INHIBITORS | HEITMEIER, KENDALL NICOLE | 1621 | §103§112DP | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18678931 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | AULAKH, CHARANJIT | 1621 | §112 | Final Rejection | — | Pending | May 30, 2024 |
| 18675743 | PYRAZOLOQUINOLINE KRAS INHIBITORS | RAHMANI, NILOOFAR | 1691 | §102 | Non-Final OA | — | Pending | May 28, 2024 |
| 18671477 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Non-Final OA | — | Pending | May 22, 2024 |
| 18640382 | USE OF JAK1 INHIBITORS FOR THE TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS AND LICHEN PLANUS (LP) | HUI, SAN MING R | 1627 | §103 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18638034 | CYCLIC UREA KRAS INHIBITORS | KIFLE, BRUCK | 1624 | §112 | Final Rejection | — | Pending | Apr 17, 2024 |
| 18625703 | NOVEL PD-1 BINDING DOMAINS | GAO, ASHLEY HARTMAN | 1678 | DP | Non-Final OA | 15d | Pending | Apr 03, 2024 |
| 18625756 | NOVEL PD-1 BINDING DOMAINS | GAO, ASHLEY HARTMAN | 1678 | §112 | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18602434 | Bicyclic Ureas As Kinase Inhibitors | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Mar 12, 2024 |
| 18598812 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF VITILIGO | VALENROD, YEVGENY | 1628 | §103DP | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18584553 | Heterocyclic Compounds As Kinase Inhibitors | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18581959 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | 1641 | §103§112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18411350 | COMBINATIONS AND USES THEREOF | DAHLE, CHUN WU | 1641 | §103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18512514 | Heteroaryl Fluoroalkenes As DGK Inhibitors | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18512625 | Heteroaryl Fluoroalkenes As DGK Inhibitors | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18373648 | ANTI-PD-1/LAG-3 BISPECIFIC ANTIBODIES AND USES THEREOF | REDDIG, PETER J | 1646 | §103Other | Non-Final OA | 27d | Pending | Sep 27, 2023 |
| 18232970 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | REDWOOD, CHRISTOPHER EVAN | 1629 | §103 | Final Rejection | 25d overdue | Pending | Aug 11, 2023 |
| 18349606 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS | DEKARSKE, MADELINE MCGUIRE | 1622 | §103Other | Final Rejection | 46d | Pending | Jul 10, 2023 |
| 18245019 | TOPICAL TREATMENT OF VITILIGO | SOROUSH, LAYLA | 1622 | §102§103§112 | Non-Final OA | — | Pending | Mar 13, 2023 |
| 18179838 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | TOWNSLEY, SARA ELIZABETH | 1629 | §112 | Final Rejection | 28d overdue | Pending | Mar 07, 2023 |
| 18176294 | TOPICAL TREATMENT OF VITILIGO BY A JAK INHIBITOR | GOTFREDSON, GAREN | 1619 | §103Other | Non-Final OA | 3d overdue | AI Ready | Feb 28, 2023 |
| 18056907 | MULTISPECIFIC BINDING MOIETIES COMPRISING PD-1 AND TGF-BRII BINDING DOMAINS | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102§103§112Other | Final Rejection | 15d | Pending | Nov 18, 2022 |
| 16791561 | CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND USES THEREOF | KATAKAM, SUDHAKAR | 1658 | §103DP | Final Rejection | — | Pending | Feb 14, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialINCYTE Corporation has 35 pending office actions as of October 2026, spread across 14 art units and 25 examiners.
Allen Chao has the most, with 4 of INCYTE Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
